Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Do Hedge Funds Love PRA Health Sciences Inc (PRAH)?

Page 1 of 2

The worries about the election and the ongoing uncertainty about the path of interest-rate increases have been keeping investors on the sidelines. Of course, most hedge funds and other asset managers have been underperforming main stock market indices since the middle of 2015. Interestingly though, smaller-cap stocks registered their best performance relative to the large-capitalization stocks since the end of the June quarter, suggesting that this may be the best time to take a cue from their stock picks. In fact, the Russell 2000 Index gained more than 15% since the beginning of the third quarter, while the Standard and Poor’s 500 benchmark returned less than 6%. This article will lay out and discuss the hedge fund and institutional investor sentiment towards PRA Health Sciences Inc (NASDAQ:PRAH).

PRA Health Sciences Inc (NASDAQ:PRAH) shareholders have witnessed an increase in hedge fund sentiment in recent months. PRAH was in 23 hedge funds’ portfolios at the end of the third quarter of 2016. There were 18 hedge funds in our database with PRAH positions at the end of the previous quarter. At the end of this article we will also compare PRAH to other stocks including Tech Data Corp (NASDAQ:TECD), Compass Minerals International, Inc. (NYSE:CMP), and Allegiant Travel Company (NASDAQ:ALGT) to get a better sense of its popularity.

Follow Pra Health Sciences Inc. (NASDAQ:PRAH)
Trade (NASDAQ:PRAH) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

dna, bio, clone, helix, medical, health, research, cell, gene, microscopic, render, tech, chemistry, molecular, liquid, life, biotechnology, technology, medicine, molecule,

everything possible/Shutterstock.com

Keeping this in mind, let’s analyze the key action surrounding PRA Health Sciences Inc (NASDAQ:PRAH).

What have hedge funds been doing with PRA Health Sciences Inc (NASDAQ:PRAH)?

Heading into the fourth quarter of 2016, a total of 23 of the hedge funds tracked by Insider Monkey were bullish on this stock, a jump of 28% from one quarter earlier. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of key hedge fund managers who were increasing their stakes significantly (or already accumulated large positions).
PRAH
According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Paul Marshall and Ian Wace’s Marshall Wace LLP has the number one position in PRA Health Sciences Inc (NASDAQ:PRAH), worth close to $48.3 million, amounting to 0.3% of its total 13F portfolio. Sitting at the No. 2 spot is Israel Englander of Millennium Management, with a $38.9 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Remaining hedge funds and institutional investors that are bullish comprise Arthur B Cohen and Joseph Healey’s Healthcor Management LP, Robert Pohly’s Samlyn Capital and Anand Parekh’s Alyeska Investment Group.

Page 1 of 2
Loading Comments...